Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From CSL Vifor

EMA Backs Approval Of Santhera’s Agamree, Pfizer’s Elrexfio & Several Other New Drugs

Four new orphan medicines were among the products recommended for pan-EU marketing approval by the European Medicines Agency this week.

Europe EU

Santhera’s Vamorolone For DMD Among Orphan Drugs Up For EU Marketing Decision

The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.

BioPharmaceutical Cancer

Travere Hopes For FDA Full Approval Despite Filspari Trial Endpoint Miss

The company said the “totality of data” from the confirmatory PROTECT trial in IgA nephropathy showed the drug slowed decline in kidney function.

Clinical Trials FDA

Sparsentan Fails In Phase III FSGS Study, But Travere Assessing Path To Approval

Travere’s drug, approved as Filspari for immunoglobulin A nephropathy, missed its eGFR primary endpoints in focal segmental glomerulosclerosis but showed meaningful improvement in proteinuria.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Vifor Pharma Group, Vifor Pharma Management Ltd./ Subsidiaries: Aspreva Pharmaceuticals Corporation
    • Galenica Group
    • Relypsa, Inc.
    • Vifor Pharma
    • Vifor-Fresenius Medical Care Renal Pharma Ltd.
    • OM Pharma
    • Sanifit Therapeutics S.A.
UsernamePublicRestriction

Register